- Home
- STGW vs NVCR Comparison
STGW vs NVCR Comparison
Compare STGW & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STGW | NVCR |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | STGW | NVCR |
|---|---|---|
| Price | $6.15 | $12.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.39 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 03-10-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,909,000,000.00 | $655,353,000.00 |
| Revenue This Year | $14.09 | $7.72 |
| Revenue Next Year | $2.59 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.39 | ★ 8.28 |
| 52 Week Low | $4.03 | $9.82 |
| 52 Week High | $7.17 | $20.05 |
Technical Indicators
Market Signals| Indicator | STGW | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 46.18 |
| Support Level | $4.94 | $10.86 |
| Resistance Level | $6.50 | $13.78 |
| Average True Range (ATR) | 0.33 | 0.70 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 82.17 | 10.04 |
Price Performance
Historical ComparisonAbout STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.